These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2624 related articles for article (PubMed ID: 24881730)

  • 41. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
    Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
    Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
    Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
    Ardiani A; Farsaci B; Rogers CJ; Protter A; Guo Z; King TH; Apelian D; Hodge JW
    Clin Cancer Res; 2013 Nov; 19(22):6205-18. PubMed ID: 24048332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
    Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
    JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
    Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
    Rathkopf DE; Beer TM; Loriot Y; Higano CS; Armstrong AJ; Sternberg CN; de Bono JS; Tombal B; Parli T; Bhattacharya S; Phung D; Krivoshik A; Scher HI; Morris MJ
    JAMA Oncol; 2018 May; 4(5):694-701. PubMed ID: 29522174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abiraterone in metastatic prostate cancer without previous chemotherapy.
    Ryan CJ; Smith MR; de Bono JS; Molina A; Logothetis CJ; de Souza P; Fizazi K; Mainwaring P; Piulats JM; Ng S; Carles J; Mulders PF; Basch E; Small EJ; Saad F; Schrijvers D; Van Poppel H; Mukherjee SD; Suttmann H; Gerritsen WR; Flaig TW; George DJ; Yu EY; Efstathiou E; Pantuck A; Winquist E; Higano CS; Taplin ME; Park Y; Kheoh T; Griffin T; Scher HI; Rathkopf DE;
    N Engl J Med; 2013 Jan; 368(2):138-48. PubMed ID: 23228172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
    Gomez-Veiga F; Szmulewitz RZ; Holzbeierlein J; Azad AA; Iguchi T; Villers A; Alcaraz A; Alekseev B; Shore ND; Rosbrook B; Zohren F; Ma J; Haas GP; Stenzl A; Armstrong AJ
    Eur Urol Oncol; 2024 Aug; 7(4):860-869. PubMed ID: 38072761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Azad AA; Iguchi T; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alcaraz A; Alekseev B; Shore ND; Gomez-Veiga F; Rosbrook B; Zohren F; Yamada S; Haas GP; Stenzl A
    J Clin Oncol; 2022 May; 40(15):1616-1622. PubMed ID: 35420921
    [No Abstract]   [Full Text] [Related]  

  • 56. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
    Ning YM; Brave M; Maher VE; Zhang L; Tang S; Sridhara R; Kim G; Ibrahim A; Pazdur R
    Oncologist; 2015 Aug; 20(8):960-6. PubMed ID: 26070917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
    Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
    Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.
    Bennett LL; Ingason A
    Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.
    Keating GM
    Drugs Aging; 2015 Mar; 32(3):243-9. PubMed ID: 25711765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 132.